The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The FLAGM regimen in younger adult patients with relapsed or refractory acute myeloid leukemia
The treatment of younger adult patients (< 65 years) with acute myeloid leukemia (AML) with induction chemotherapy, including cytarabine (Ara-C) and an anthracycline, has high complete remission (CR) rates, however, approximately 50% of patients relapse within three years.1 The development of an effective salvage therapy for patients with relapsed or refractory (R/R) AML is therefore critical.
Dr. Nahoko Hatsumi from the Saiseikai Maebashi Hospital, Maebashi, Japan, and colleagues published a single arm, multicenter phase II study in the International Journal of Hematology evaluating the efficacy and toxicity of the FLAGM regimen in patients with R/R AML.2 Between June 2004 and February 2008, enrolled patients (n = 41; median age = 52 years; range, 18–64) received the FLAGM regimen, consisting of filgrastim (G-CSF; 300 µg/m2; subcutaneous; at start of regimen and every 24 h thereafter; total doses = 4), fludarabine (15 mg/m2; 30 min infusion; 20 h after start of regimen; every 12 h thereafter; total doses = 8), Ara-C (2 g/m2; 3 h infusion; 4 h after start of fludarabine; every 12 h, total doses = 8), and mitoxantrone (10 mg/m2; daily; 30 min infusion with Ara-C; at 72, 96, and 120 h after regimen start). The primary endpoint of this study was the CR rate following one course of therapy.
Key findings:
Efficacy
- Median follow-up: 33 months (range, 4–46)
- Primary study endpoint was met, with CR rate in all evaluable patients of 73% (95% CI, 58–84)
- CR rate in primary refractory patients: 50%
- CR rate in patients in first relapse: 78% (95% CI, 61–89)
- CR rate in patients refractory to salvage therapy following first relapse: 100%
- Patients receiving allogeneic stem cell transplantation (SCT) following FLAGM regimen: 80% (33/41)
- For patients who achieved a CR following FLAGM regimen, 80% (24/30) received SCT during CR
- For all evaluable patients, the 2-year overall survival rate: 39.4% (95% CI, 25.2–55.6)
- For patients achieving a CR (n = 30), the 2-year relapse-free survival rate: 43.5% (95% CI, 26.7–61.9)
Safety
- All patients experienced grade IV leukopenia and thrombocytopenia
- One early death occurred due to pneumonia within 30 days, all other patients recovered
- The most common grade III/IV adverse events include: nausea/vomiting (15%), diarrhea (7%), elevated liver enzymes (7%), stomatitis (2%), and pyrexia (2%)
- During the follow-up period, a total of 26 deaths occurred
The study investigators concluded that this phase II study showed the FLAGM was an effective and safe salvage therapy option for patients with R/R AML. In addition to this, the authors also demonstrated that the FLAGM regimen enabled a high proportion of patients to receive SCT.
References